title: Expression of CD44 standard and isoforms V3 and V6 in uterine smooth muscle tumors: a possible diagnostic tool for the diagnosis of leiomyosarcoma.
abstract: Alterations of CD44 proteins, a family of cell adhesion molecule, have been linked with tumorigenesis, carcinogenesis, and prognosis in various neoplasms. Our aims were to evaluate and compare CD44 isoforms expression patterns in normal myometrium, uterine leiomyomas, and leiomyosarcomas and to correlate CD44 expression with clinicopathologic parameters. Fresh (n = 15) and formalin-fixed, paraffin-embedded (n = 76) tissues samples of myometrium, leiomyomas, and leiomyosarcomas were used for immunoblotting and immunohistochemistry, respectively. Semiquantitative evaluation was made after immunostaining. Monoclonal antibodies were used. By immunoblotting in myometrium and leiomyomas samples, we observed a band at 85 kd, corresponding to the apparent molecular weight of CD44s, and bands at 140 kd with the monoclonal antibodies against CD44v3 and CD44v6. In leiomyosarcomas, CD44s and CD44v6 were detected, but not CD44v3. By immunohistochemistry, decreased CD44s expression was found in leiomyomas and leiomyosarcomas (73.9% +/- 16.6% and 82.1% +/- 20.7%, respectively) compared with myometrium (97.3% +/- 6.2%; P < .0001). No CD44v6 staining was detected in myometrium, leiomyomas, and leiomyosarcomas. No CD44v3 expression was detected in leiomyosarcomas, whereas myometrium and leiomyomas expressed CD44v3. For the diagnosis of leiomyosarcoma, the absence of CD44v3 staining had a sensitivity, specificity, and positive and negative predictive values of 100%. In patients with recurrence of leiomyosarcomas, CD44s expression was decreased (P = .03). We conclude that CD44s immunostaining in leiomyosarcomas may have prognostic significance. The loss of CD44v3 expression could be used as a putative diagnostic tool for uterine leiomyosarcomas.
authors.affiliation: Laboratoire de Biologie Cellulaire, INSERM U327, Faculté de Medecine Xavier Bichat Université Paris, Paris, France.
authors.forename: C
authors.initials: C
authors.lastname: Poncelet
authors.forename: F
authors.initials: F
authors.lastname: Walker
authors.forename: P
authors.initials: P
authors.lastname: Madelenat
authors.forename: A F
authors.initials: AF
authors.lastname: Bringuier
authors.forename: J Y
authors.initials: JY
authors.lastname: Scoazec
authors.forename: G
authors.initials: G
authors.lastname: Feldmann
authors.forename: E
authors.initials: E
authors.lastname: Darai
mesh_terms: D000328:Adult; D000368:Aged; D015153:Blotting, Western; D005260:Female; D006023:Glycoproteins / Q000276:immunology / Q000378:metabolism*; D006801:Humans; D018960:Hyaluronan Receptors / Q000276:immunology / Q000378:metabolism*; D007124:Immunoenzyme Techniques; D019394:Ki-67 Antigen / Q000276:immunology / Q000378:metabolism; D007889:Leiomyoma / Q000175:diagnosis / Q000378:metabolism* / Q000473:pathology; D007890:Leiomyosarcoma / Q000175:diagnosis / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009215:Myometrium / Q000378:metabolism; D011379:Prognosis; D014594:Uterine Neoplasms / Q000175:diagnosis / Q000378:metabolism* / Q000473:pathology
chemical_list: C121450:CD44V3,8-10; C112697:CD44v6 antigen; D006023:Glycoproteins; D018960:Hyaluronan Receptors; D019394:Ki-67 Antigen